PredictImmune, Addenbrooke's Hospital Sign Agreement to Provide IBD Diagnostic in UK, Ireland

Apr 02, 2019

|

NEW YORK (GenomeWeb) – PredictImmune announced today that it has entered a commercial agreement with Addenbrooke's Hospital — part of Cambridge University Hospitals National Health Service Foundation Trust — to provide the company's PredictSure IBD prognostic assay to clinicians and gastroenterologists in the UK and Ireland.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

PredictImmune, Addenbrooke's Hospital Sign Agreement to Provide IBD Diagnostic in UK, Ireland

To read the full story....

Breaking News

Pro-Lab Diagnostics Nabs FDA Emergency Use Authorization for Molecular SARS-CoV-2 Test

HHS Invests $6.5M in Aegis Sciences, Sonic Healthcare USA to Expand Coronavirus Testing Capacity

Myriad Genetics Q4 Revenues Plummet 57 Percent on Coronavirus Pandemic Pressures

Progenity Q2 Revenues Fall 70 Percent in First Earnings Report Since IPO

In Brief This Week: Thermo Fisher Scientific, Quanterix, BGI, Illumina, and More

Aspira Q2 Revenues Down 32 Percent

Featured White Papers

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

Many Initiatives Turning to RT-LAMP as Alternative to PCR for Rapid COVID-19 Screening Assays

HHS Invests $6.5M in Aegis Sciences, Sonic Healthcare USA to Expand Coronavirus Testing Capacity

Thermo Fisher Scientific Terminates Qiagen Acquisition Agreement

UK Reports First Results From At-Home Antibody Testing Program for SARS-CoV-2

Myriad Genetics Q4 Revenues Plummet 57 Percent on Coronavirus Pandemic Pressures

Sponsorships